Philippe Chambon, M.D., Ph.D., CEO

Oct. 12 | 11:15pm | Ecolab Life Sciences Ballroom 

Paris, France


EG427 is unlocking the full potential of gene therapy for the treatment of localized severe chronic diseases. Our proprietary platform of non-replicative herpes-based vectors is uniquely able to modulate the activity of various neurons subtypes. With an IND slated for early 2024, we will be the next company, to have a non-replicative herpes-based construct in human clinical trial, and the first one to address sensory neuron-based pathologies. Our first product targets a broad range of conditions linked to bladder dysfunction originating from its sensory innervation, starting with a human POC in neurogenic bladder post Spinal Cord Injury.

By using this website you agree to accept our Privacy Policy and Terms & Conditions